Actinium Pharmaceuticals Files Q1 2025 10-Q Report

Ticker: ATNM · Form: 10-Q · Filed: May 9, 2025 · CIK: 1388320

Actinium Pharmaceuticals, Inc. 10-Q Filing Summary
FieldDetail
CompanyActinium Pharmaceuticals, Inc. (ATNM)
Form Type10-Q
Filed DateMay 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, quarterly-report, pharmaceuticals

TL;DR

Actinium Pharma filed its Q1 2025 10-Q. Standard quarterly update.

AI Summary

Actinium Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company, incorporated in Delaware, is in the pharmaceutical preparations industry. Its principal executive offices are located at 100 Park Ave., New York, NY. The filing is a standard 10-Q report.

Why It Matters

This filing provides investors with an update on Actinium Pharmaceuticals' financial performance and operational status for the first quarter of 2025.

Risk Assessment

Risk Level: low — This is a routine quarterly filing and does not contain immediate, significant new risks.

Key Players & Entities

  • Actinium Pharmaceuticals, Inc. (company) — Registrant
  • March 31, 2025 (date) — Quarterly period end date
  • 100 Park Ave., 23rd Floor (location) — Principal Executive Offices
  • New York, NY (location) — City and State of Principal Executive Offices
  • 10017 (location) — Zip Code of Principal Executive Offices
  • Delaware (location) — State of Incorporation
  • 001-36374 (other) — Commission File Number

FAQ

What is the primary purpose of this filing?

This filing is a Form 10-Q, a quarterly report required by the SEC for the period ended March 31, 2025.

What is the company's full legal name?

The company's full legal name is Actinium Pharmaceuticals, Inc.

In which state was Actinium Pharmaceuticals, Inc. incorporated?

Actinium Pharmaceuticals, Inc. was incorporated in Delaware.

What is the address of the company's principal executive offices?

The company's principal executive offices are located at 100 Park Ave., 23rd Floor, New York, NY 10017.

What is the Commission File Number for Actinium Pharmaceuticals, Inc.?

The Commission File Number for Actinium Pharmaceuticals, Inc. is 001-36374.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding Actinium Pharmaceuticals, Inc. (ATNM).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.